Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents
Open Access
- 1 October 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (10), 4027-4032
- https://doi.org/10.1128/aac.48.10.4027-4032.2004
Abstract
The MICs of LBM415, a new peptide diformylase inhibitor, were evaluated and ranged from 0.03 to 4.0 μg/ml for 300 pneumococci, irrespective of their β-lactam, macrolide, and quinolone susceptibilities. By comparison, vancomycin, teicoplanin, linezolid, and quinupristin-dalfopristin were also active, with MICs ≤2.0 μg/ml. Gatifloxacin and moxifloxacin were the most active quinolones tested, while the MICs of the β-lactams rose with those of penicillin G. LBM415 at two times the MIC was bactericidal (99.9% killing) against six strains after 24 h.Keywords
This publication has 23 references indexed in Scilit:
- Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM 415), a novel inhibitor of bacterial peptide deformylaseClinical Microbiology & Infection, 2004
- Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolatesDiagnostic Microbiology and Infectious Disease, 2004
- Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolatesJournal of Antimicrobial Chemotherapy, 2004
- Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitorDiagnostic Microbiology and Infectious Disease, 2004
- Antipneumococcal and Antistaphylococcal Activities of Ranbezolid (RBX 7644), a New Oxazolidinone, Compared to Those of Other AgentsAntimicrobial Agents and Chemotherapy, 2003
- Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolidJournal of Antimicrobial Chemotherapy, 2000
- OxazolidinonesDrugs, 2000
- Fluoroquinolone Resistance inStreptococcus pneumoniaeNew England Journal of Medicine, 1999
- Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococciJournal of Antimicrobial Chemotherapy, 1995
- Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829Journal of Antimicrobial Chemotherapy, 1993